Preclinical evaluation of microRNA-34b/c delivery for malignant pleural mesothelioma.
Acta Med Okayama
; 68(1): 23-6, 2014.
Article
em En
| MEDLINE
| ID: mdl-24553485
ABSTRACT
The microRNA-34s (miR-34s) have p53 response elements in their 5'-flanking regions and demonstrate tumor-suppressive functions. In malignant pleural mesothelioma (MPM), we previously reported that expression of miR-34b and miR-34c (miR-34b/c) was frequently downregulated by methylation in MPM cell lines and primary tumors. The forced overexpression of miR-34b/c showed significant antitumor effects with the induction of apoptosis in MPM cells. In this study, we examined the in vivo antitumor effects of miR-34b/c using adenovirus vector on MPM. We subcutaneously transplanted NCI-H290, a human MPM cell line, into BALB/C mice and injected adenovirus vector expressing miR-34b/c, luciferase driven by the cytomegalovirus promoter (Ad-miR-34b/c or Ad-Luc), or PBS control into tumors over 5mm in diameter. A statistically significant growth inhibition of the tumor volume was observed in the Ad-miR-34b/c group from day 6 onward compared to the Ad-Luc group. The inhibition rate of Ad-miR-34b/c, compared to the tumor volume treated with Ad-Luc, was 58.6% on day 10 and 54.7% on day13. Our results indicate that adenovirus-mediated miR-34b/c gene therapy could be useful for the clinical treatment of MPM.
Buscar no Google
Base de dados:
MEDLINE
Assunto principal:
Neoplasias Pleurais
/
Terapia Genética
/
MicroRNAs
/
Neoplasias Pulmonares
/
Mesotelioma
Limite:
Animals
/
Female
/
Humans
Idioma:
En
Ano de publicação:
2014
Tipo de documento:
Article